HK1246687A1 - 治療與帕金遜症治療相關的運動失調及其副作用的方法 - Google Patents
治療與帕金遜症治療相關的運動失調及其副作用的方法Info
- Publication number
- HK1246687A1 HK1246687A1 HK18106452.8A HK18106452A HK1246687A1 HK 1246687 A1 HK1246687 A1 HK 1246687A1 HK 18106452 A HK18106452 A HK 18106452A HK 1246687 A1 HK1246687 A1 HK 1246687A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- parkinson
- methods
- side effects
- movement disorders
- disease treatments
- Prior art date
Links
- 208000019430 Motor disease Diseases 0.000 title 1
- 208000016285 Movement disease Diseases 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103036P | 2015-01-13 | 2015-01-13 | |
| PCT/US2016/013206 WO2016115223A1 (en) | 2015-01-13 | 2016-01-13 | Methods of treating motor and movement disorders and side effects thereof associated with parkinson's disease treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1246687A1 true HK1246687A1 (zh) | 2018-09-14 |
Family
ID=56406325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18106452.8A HK1246687A1 (zh) | 2015-01-13 | 2018-05-17 | 治療與帕金遜症治療相關的運動失調及其副作用的方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20180263975A1 (zh) |
| EP (1) | EP3244892A4 (zh) |
| CA (1) | CA2973701A1 (zh) |
| HK (1) | HK1246687A1 (zh) |
| WO (1) | WO2016115223A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109689036A (zh) | 2016-07-11 | 2019-04-26 | 康特拉医药公司 | 用于治疗早晨运动不能的脉冲药物输送系统 |
| CN113453683A (zh) * | 2018-12-20 | 2021-09-28 | 康特拉医药股份有限公司 | 运动障碍的治疗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6417210B1 (en) * | 1998-01-09 | 2002-07-09 | Mor-Research Applications Ltd. | Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa |
| US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| JP5792061B2 (ja) * | 2008-05-30 | 2015-10-07 | サイコジェニックス・インコーポレーテッドＰｓｙｃｈｏｇｅｎｉｃｓ Ｉｎｃ． | 神経及び精神障害の治療法 |
| US20110183995A1 (en) * | 2008-06-24 | 2011-07-28 | Neurosearch A/S | Eltoprazine for suppression of l-dopa induced dyskinesias |
| TW201029995A (en) * | 2008-12-05 | 2010-08-16 | Merz Pharma Gmbh & Co Kgaa | Use of eltoprazine for the treatment of L-DOPA-induced dyskinesia |
| US20130033139A1 (en) * | 2011-08-01 | 2013-02-07 | Garlock Sealing Technologies, Llc | Method of Securing a Sealing Device to a Housing with a Limited Bore Diameter |
-
2016
- 2016-01-13 EP EP16737796.9A patent/EP3244892A4/en not_active Withdrawn
- 2016-01-13 US US15/542,286 patent/US20180263975A1/en not_active Abandoned
- 2016-01-13 CA CA2973701A patent/CA2973701A1/en not_active Abandoned
- 2016-01-13 WO PCT/US2016/013206 patent/WO2016115223A1/en active Application Filing
-
2018
- 2018-05-17 HK HK18106452.8A patent/HK1246687A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180263975A1 (en) | 2018-09-20 |
| CA2973701A1 (en) | 2016-07-21 |
| EP3244892A4 (en) | 2018-09-19 |
| WO2016115223A1 (en) | 2016-07-21 |
| EP3244892A1 (en) | 2017-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265566A (en) | Methods for the treatment of mitochondrial and metabolic disorders | |
| IL274648A (en) | Promote new catecholamine drugs for use in the treatment of Parkinson's disease | |
| IL246999A0 (en) | Methods for treating Alzheimer's disease | |
| PL3405215T3 (pl) | Sposoby leczenia choroby danona i innych zaburzeń autofagii | |
| EP3377118A4 (en) | METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
| IL236107A0 (en) | Treatment of side effects such as motor and movement disorders related to the treatment of Parkinson's disease | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| IL249439A0 (en) | A compound and method for the treatment of neurological diseases and brain injury | |
| PT3302454T (pt) | Composições para utilização no tratamento da doença de parkinson e distúrbios associados | |
| IL267229A (en) | Methods of treating ocular disorders | |
| IL275654A (en) | Methods of treating CASTOR-related disorders | |
| EP3347486A4 (en) | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| GB2561747B (en) | Composition for treating motor neuron diseases and use thereof | |
| HK1246687A1 (zh) | 治療與帕金遜症治療相關的運動失調及其副作用的方法 | |
| EP3554496A4 (en) | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | |
| IL275349A (en) | Use of hM4Di in the treatment of seizure disorders | |
| EP3538095A4 (en) | METHOD FOR TREATING MORBUS PARKINSON | |
| IL274838A (en) | Use of MIR101 or MIR128 in the treatment of seizure disorders | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| IL265656A (en) | Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease | |
| HK1258884A1 (zh) | 用於治療竇疾病和病症的組合物和方法 | |
| HK1258207A1 (zh) | 基於鑒別和改善肝功能障礙來診斷和治療帕金森病 | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| EP3426803A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF MORBUS PARKINSON | |
| GB201504144D0 (en) | Treatment of Parkinson's disease |